Alpha Fusion

About Alpha Fusion

Alpha Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing radiopharmaceuticals for oncology. The company was founded in 2021 and is headquartered in Osaka, Japan. It was established to commercialize research originating from Osaka University and the Japan Science and Technology Agency (JST) OPERA QiSS program. The company's CEO is Sunao Fujioka.

The core of Alpha Fusion's business is the development of Targeted Alpha Therapy (TAT), a method that uses alpha-emitting particles to precisely target and destroy cancer cells. The business model revolves around the research, development, and eventual commercialization of these novel cancer treatments. The company aims to provide new options for cancer patients, particularly those with conditions that are difficult to treat with existing methods. Their strategy includes advancing their proprietary drug pipelines through clinical trials and establishing a global supply chain for their therapies by collaborating with partners and utilizing cyclotrons for production.

Alpha Fusion's therapeutic agents are based on the isotope Astatine-211 (211At). This isotope emits alpha particles that can kill cancer cells and has a short half-life of 7.2 hours, which is considered beneficial for patient safety. The company has multiple products in its development pipeline. Its leading candidate, af-001, is a treatment for refractory thyroid cancer and is currently in Phase 1 clinical trials. Another key candidate, af-002, targets prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer and has also entered Phase 1 trials. The company has made significant financial strides, securing Series A funding in March 2023 and a Series B round of ¥1.02 billion in October 2024 to accelerate its research, enhance its supply chain, and prepare for company-sponsored clinical trials.